A groundbreaking new study from the Danish Centre for Universal Human Condition Alignment (DCUHCA) has officially confirmed that 98% of the global population now meets the diagnostic criteria for either Attention-Deficit/Hyperactivity Disorder (ADHD) or Autism Spectrum Disorder (ASD). The monumental finding represents a significant leap forward in validating nearly every human experience as a diagnosable condition, ensuring that the vast majority of individuals can finally access the tailored support and medication they never knew they needed.
"For too long, vast swathes of humanity have struggled with daily life without the comforting embrace of a formal diagnosis," stated Dr. Ingrid Kjeldsen, lead researcher at DCUHCA. "Our expanded diagnostic parameters now ensure that if you've ever misplaced your keys, had an awkward conversation, preferred a quiet evening to a loud party, or simply exist in a state of mild, chronic disorientation, you're officially part of the neurodivergent community. This isn't just about inclusion and equity; it's about optimizing the human condition by medicalizing it from birth to grave."
The study, which analyzed billions of data points including social media usage patterns, grocery shopping habits, and the inability to sit through a Netflix series without checking one's phone, concluded that the "typical" individual of 2026 is virtually indistinguishable from diagnostic profiles of clinically impaired individuals from a decade ago. This shift, experts suggest, isn't due to a sudden global epidemic of neurodevelopmental disorders, but rather a heroic effort by the medical establishment to ensure nobody feels left out of the burgeoning mental health economy.
Industry leaders are already retooling their entire business models. Pharmaceutical companies have begun adapting marketing strategies, anticipating a near-universal demand for "focus aids," "social lubricant" medications, and "sensory management" apparel. "We're not just treating conditions anymore; we're optimizing the baseline human experience," remarked a spokesperson for PharmaCorp, requesting anonymity to avoid shareholder accusations of under-promising on the global market potential. "Why settle for being merely 'normal' when you can be 'diagnosed, managed, and perpetually medicated'?"
Educational institutions are also embracing the change, with universities announcing new "Neurodiversity Affirmation Centers" that will provide "safe spaces" for students struggling with the inherent demands of higher education, such as showing up on time or completing assignments. Corporations are following suit, implementing "neuro-inclusive" workspaces designed to accommodate the 98% of employees who now qualify for special accommodations for everything from fluorescent lighting to the expectation of coherent communication. The move is expected to drastically cut productivity, but significantly boost employee "well-being" scores.
The DCUHCA is now reportedly working on refining diagnostic criteria for "Existential Dread Disorder," "Chronic Screen Gaze Syndrome," and "Generalized Anxiety About Everything," aiming to hit a perfect 100% diagnostic rate across all demographics by Q4. Their ultimate goal: a world where every single human trait, preference, or minor inconvenience is not just recognized, but officially pathologized and, crucially, billable.